139 related articles for article (PubMed ID: 32898795)
1. Structure-activity relationship study of novel quinazoline-based 1,6-naphthyridinones as MET inhibitors with potent antitumor efficacy.
Zhuo LS; Wu FX; Wang MS; Xu HC; Yang FP; Tian YG; Zhao XE; Ming ZH; Zhu XL; Hao GF; Huang W
Eur J Med Chem; 2020 Dec; 208():112785. PubMed ID: 32898795
[TBL] [Abstract][Full Text] [Related]
2. 2,7-naphthyridinone-based MET kinase inhibitors: A promising novel scaffold for antitumor drug development.
Zhuo LS; Xu HC; Wang MS; Zhao XE; Ming ZH; Zhu XL; Huang W; Yang GF
Eur J Med Chem; 2019 Sep; 178():705-714. PubMed ID: 31229873
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and anti-tumor activity of [1,4] dioxino [2,3-f] quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2.
Wei D; Fan H; Zheng K; Qin X; Yang L; Yang Y; Duan Y; Zhang Q; Zeng C; Hu L
Bioorg Chem; 2019 Jul; 88():102916. PubMed ID: 31026719
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of new MET inhibitors with 1,6-naphthyridinone scaffold.
Wang MS; Zhuo LS; Yang FP; Wang WJ; Huang W; Yang GF
Eur J Med Chem; 2020 Jan; 185():111803. PubMed ID: 31677447
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate.
Chen T; Zhuo LS; Liu PF; Fang WR; Li YM; Huang W
Eur J Med Chem; 2020 Apr; 192():112174. PubMed ID: 32113049
[TBL] [Abstract][Full Text] [Related]
6. Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2.
Xu H; Wang M; Wu F; Zhuo L; Huang W; She N
Bioorg Med Chem; 2020 Jun; 28(12):115555. PubMed ID: 32503697
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2018 Feb; 76():154-165. PubMed ID: 29175587
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction.
Nan X; Zhang J; Li HJ; Wu R; Fang SB; Zhang ZZ; Wu YC
Eur J Med Chem; 2020 Aug; 200():112470. PubMed ID: 32505087
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel quinazoline derivatives as potent PI3Kδ inhibitors with high selectivity.
Teng Y; Li X; Ren S; Cheng Y; Xi K; Shen H; Ma W; Luo G; Xiang H
Eur J Med Chem; 2020 Dec; 208():112865. PubMed ID: 32987316
[TBL] [Abstract][Full Text] [Related]
11. Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Bioorg Med Chem; 2014 Sep; 22(17):4735-44. PubMed ID: 25082515
[TBL] [Abstract][Full Text] [Related]
12. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
Nan X; Li HJ; Fang SB; Li QY; Wu YC
Eur J Med Chem; 2020 May; 193():112241. PubMed ID: 32200199
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors.
Zhang L; Yang Y; Zhou H; Zheng Q; Li Y; Zheng S; Zhao S; Chen D; Fan C
Eur J Med Chem; 2015 Sep; 102():445-63. PubMed ID: 26310890
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors.
Luo G; Ma Y; Liang X; Xie G; Luo Y; Zha D; Wang S; Yu L; Zheng X; Wu W; Zhang C
Bioorg Chem; 2020 Nov; 104():104356. PubMed ID: 33142417
[TBL] [Abstract][Full Text] [Related]
17. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidine derivatives containing 1,8-naphthyridine-4-one fragment.
Zhang J; Chen P; Duan Y; Xiong H; Li H; Zeng Y; Liang G; Tang Q; Wu D
Eur J Med Chem; 2021 Apr; 215():113273. PubMed ID: 33601310
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of novel substituted naphthyridines as potential c-Met kinase inhibitors based on MK-2461.
Wu JF; Liu MM; Huang SX; Wang Y
Bioorg Med Chem Lett; 2015 Aug; 25(16):3251-5. PubMed ID: 26077488
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of quinoxaline derivatives as specific c-Met kinase inhibitors.
Kim SC; Boggu PR; Yu HN; Ki SY; Jung JM; Kim YS; Park GM; Ma SH; Kim IS; Jung YH
Bioorg Med Chem Lett; 2020 Jul; 30(13):127189. PubMed ID: 32371098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
